A CRISPR-Cas9 gene-editing platform targeting S-RNase and related gametophytic self-incompatibility factors to unlock interspecific crosses in cultivated potato and its wild relatives. This technology enables breeders to access valuable wild species traits previously blocked by reproductive barriers, accelerating trait introgression for improved potato varieties.
This research program develops and applies CRISPR-Cas9 gene-editing tools to overcome gametophytic self-incompatibility barriers that limit interspecific hybridization in Solanum species. By generating knockouts of S-RNase and other key candidate genes, the team enables crosses between cultivated potato and its wild relatives that were previously inaccessible to breeders. The work addresses a critical bottleneck in potato breeding by removing reproductive barriers, allowing the introgression of valuable traits such as disease resistance, abiotic stress tolerance, and quality characteristics from wild species into cultivated backgrounds. The platform has already demonstrated proof of concept, with S-RNase knockouts producing self-compatible potato lines. Ongoing RNA expression analysis of naturally self-compatible Solanum verrucosum aims to uncover additional genetic factors that could further expand crossing capabilities.
Core technology and approach:
Key features and benefits:
The technology is at an early-to-mid stage of development (TRL 3-4). S-RNase knockouts have been generated and validated to impart self-compatibility in cultivated potato, establishing proof of concept. The research team is currently conducting controlled interspecific crosses and generating RNA expression data to validate the role of candidate genes in interspecific compatibility. The project is estimated to take six months to complete, with the team seeking partnership funding to support key personnel and optimize RNA expression data processing. Validation through pollen tube growth analysis and statistical evaluation is underway to confirm the significance of each targeted barrier in enabling successful interspecific hybridization.
Michigan State University is a major public land‑grant research university with a comprehensive academic portfolio and a large research enterprise. Industry partners engage through an on‑campus U.S. Department of Energy national user facility and shared core laboratories with user access. The university provides a chemical process scale‑up pilot plant on Michigan’s lakeshore, a research and technology park, and a Grand Rapids health innovation campus linking researchers with clinical partners. A statewide extension network supports field deployment and workforce training across Michigan’s manufacturing corridor. Research is backed by competitive federal funding from NSF, NIH, DOE, USDA, and DoD, while dedicated tech transfer and corporate engagement teams—supported by an affiliated research foundation—accelerate IP, licensing, startups, and sponsored research.